Loading...
•
Sep 30, 2024
Personalis Q3 2024 Earnings Report
Personalis's financial performance increased due to biopharma growth and strategic financing.
Key Takeaways
Personalis reported a 41% year-over-year increase in revenue, driven by a 96% increase in biopharma revenue. The company raised its 2024 revenue guidance and secured significant financing, extending its cash runway into the first half of 2027.
Total company revenue increased by 41% year-over-year to $25.7 million.
Biopharma revenue grew by 96% year-over-year to $15.7 million.
The company delivered 945 total molecular tests, a 68% increase compared to the prior quarter.
Cash balance of $143.7 million extends the expected runway into the first half of 2027.
Revenue by Segment
Forward Guidance
Personalis expects total company revenue in the range of $83 to $84 million for the full year 2024, an increase from prior guidance of $79 to $81 million. For the fourth quarter of 2024, Personalis expects total company revenue in the range of $15 to $16 million.
Positive Outlook
- Total company revenue in the range of $83 to $84 million for the full year 2024.
- Revenue from pharma tests, enterprise sales, and all other customers in the range of $76 to $77 million for the full year 2024.
- Cash usage in the range of $53 to $55 million for the full year 2024.
- Total company revenue in the range of $15 to $16 million for the fourth quarter of 2024.
- Revenue from pharma tests, enterprise sales, and other customers in the range of $15 to $16 million for the fourth quarter of 2024.
Challenges Ahead
- Revenue from population sequencing is expected to be zero for the fourth quarter of 2024.
- Revenue from population sequencing of approximately $7 million for the full year 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...